SynthesisPloS one2025
Sudden cardiac death in adults living with HIV: A systematic review.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prolonged QT Interval in HIV-1 Infected Humanized Mice Treated Chronically with Dolutegravir/Tenofovir Disoproxil Fumarate/Emtricitabine.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeople living with HIV (PLWH) have rising life expectancy, and robust evidence shows they are also at increased risk of cardiovascular disease. However, sudden cardiac death (SCD) for PLWH on antiretroviral therapy (ART) has received little attention. Our systematic review examines the quantitative adult PLWH SCD risk literature with a sub-focus of PLWH on ART.
methodsWe conducted systematic searches of PubMed, Embase, CENTRAL, CINAHL, Scopus, and Clinicaltrials.gov for peer-reviewed population studies using search terms "sudden cardiac death" AND ("HIV" OR "human immunodeficiency virus") until 20 June 2025. Two reviewers analysed papers meeting eligibility criteria for their SCD classification methodology including for, but not limited to, comparability, generalizability, and misclassification biases including using the Newcastle-Ottawa Scale.
resultsThe eight eligible studies included ~98 436 PLWH and demonstrated that males PLWH experience elevated SCD risk compared to the general population. One study with 97% male participants found a hazard ratio (HR) of 1.14 (95% CI: 1.04-1.25) for PLWH compared to non-PLWH. In another, comparing viral load groups of ≥500 vs < 500 found a HR of 1.33 (95% CI: 1.04-1.71) for PLWH with CD4 ≥ 500 compared to HIV-negative HR of 1.03 (95% CI: 0.90-1.18). An autopsy study's male sex arm found a mortality rate ratio for PLWH compared to a reference of 1.34 (95% CI: 0.62-2.87).
conclusionsThe limited available research provides evidence that while SCD risk for male PLWH is elevated, maintaining HIV-RNA plasma viral load suppression and ≥200 CD4+ cells/mm3 counts (ideally higher) likely lowers the risk of SCD to a rate that is approaching comparability to the general population. The risk of SCD in women living with HIV is still unknown, due to small sample sizes, as the majority of the participants in the PLWH studies were male.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.